Does COPD stand for "COmorbidity with Pulmonary Disease"?

European Respiratory Journal

Volumn 45, Issue 1, 2015, Pages 14-17

  Vanfleteren, Lowie E G W ^a  

^a CIRO+   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT;

AGING; ALPHA 1 ANTITRYPSIN DEFICIENCY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; CLINICAL FEATURE; COMORBIDITY; DISEASE EXACERBATION; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERINFLATION; LUNG CANCER; MENTAL DISEASE; MORTALITY; NONINVASIVE VENTILATION; PATIENT CARE; PHENOTYPIC VARIATION; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; COMPLICATION; FEMALE; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84920588490     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00148014     Document Type: Review

References (31)

1. FitzGerald JM, Poureslami I. The need for humanomics in the era of genomics and the challenge of chronic disease management. Chest 2014; 146: 10-12.
2. Campos MA, Lascano J. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy. Ther Adv Respir Dis 2014 [In press DOI: 10.1177/1753465814542243].
3. Gompelmann D, Eberhardt R, Herth FJ. Endoscopic lung volume reduction. A European perspective. Ann Am Thorac Soc 2013; 10: 657-666.
4. Kohnlein T, Windisch W, Kohler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2: 698-705.
5. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013; 41: 1252-1256.
6. Faner R, Cruz T, Lopez-Giraldo A, et al. Network medicine, multimorbidity and the lung in the elderly. Eur Respir J 2014; 44: 775-788.
7. Clini EM, Beghe B, Fabbri LM. Chronic obstructive pulmonary disease is just one component of the complex multimorbidities in patients with COPD. Am J Respir Crit Care Med 2013; 187: 668-671.
8. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-180.
9. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-735.
10. Quint JK, Herrett E, Bhaskaran K, et al. Effect of beta blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013; 347: f6650
11. Harrison MT, Short P, Williamson PA, et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax 2014; 69: 609-615.
12. Petersen H, Sood A, Meek PM, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest 2014; 145: 695-703.
13. Sexton P, Metcalf P, Kolbe J. Respiratory effects of insulin sensitisation with metformin: a prospective observational study. COPD 2014; 11: 133-142.
14. Gershon AS, Mecredy GC, Guan J, et al. Quantifying comorbidity in individuals with COPD: a population study. Eur Respir J 2015; 45: 51-59.
15. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
16. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.
17. Campo G, Guastaroba P, Marzocchi A, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest 2013; 144: 750-757.
18. Regan EA, Radcliff TA, Henderson WG, et al. Improving hip fractures outcomes for COPD patients. COPD 2013; 10: 11-19.
19. Ratschen E, Britton J, McNeill A. The smoking culture in psychiatry: time for change. Br J Psychiatry 2011; 198: 6-7.
20. Olivier D, Lubman DI, Fraser R. Tobacco smoking within psychiatric inpatient settings: biopsychosocial perspective. Aust NZ J Psychiatry 2007; 41: 572-580.
21. Freixa X, Portillo K, Paré C, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J 2013; 41: 784-791.
22. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012; 39: 51-58.
23. Vanfleteren LE, Franssen FM, Uszko-Lencer NH, et al. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol 2011; 108: 1669-1674.
24. McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012; 39: 1097-1103.
25. Beghe B, Verduri A, Roca M, et al. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J 2013; 41: 993-995.
26. Graat-Verboom L, Wouters EF, Smeenk FW, et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 2009; 34: 209-218.
27. Sekine Y, Katsura H, Koh E, et al. Early detection of COPD is important for lung cancer surveillance. Eur Respir J 2012; 39: 1230-1240.
28. Machado MC, Vollmer WM, Togeiro SM, et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 2010; 35: 132-137.
29. Hegerl U, Mergl R. Depression and suicidality in COPD: understandable reaction or independent disorders? Eur Respir J J 2014; 44: 734-743.
30. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. www.goldcopd.org/uploads/users/files/GOLD-Report- 2014-Jun11.pdf Date last accessed: August 2014. Date last updated: June 11, 2014.
31. Fabbri LM, Boyd C, Boschetto P, et al. How to integrate multiple comorbidities in guideline development: article 10 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc 2012; 9: 274-281.